Table 2.
Subgroup analysis between CCP-treated patients alive and died.
| Parameters | Alive n = 354 (87.4%) |
Died n = 51 (12.6%) |
p |
|---|---|---|---|
| Median age, years (IQR) |
66 (55.2–76.3) |
77 (67.8–81.8) |
<0.001 |
| Sex (males/females), number (ratio) |
218/136 (1.6) |
33/18 (1.8) |
NS |
| Median BMI (kg/m2) (IQR) |
24.7 (22.9–28.6) |
31.1 (27.5–35–5) |
<0.001 |
| Comorbidities, n (%) - <3 - ≥3 |
233/293 (79.5) 60/293 (20.5) |
8/31 (25.8) 23/31 (74.2) |
<0.001 |
| PaO2/FiO2, median (IQR) |
169.5 (139.2–231.0) |
92.0 (67.0–138.0) |
< 0.001 |
| PaO2/FiO2, n (%) 1 - <150 - ≥150 |
122/354 (34.5) 232/354 (65.5) |
38/51 (74.5) 13/51 (25.5) |
<0.001 |
| Hospital department, n (%) - Low intensity - Intermediate/high intensity |
255/354 (72.0) 99/354 (28.0) |
26/51 (51.0) 25/51 (49.0) |
0.004 |
| ABO blood type, n (%) - O - Non-O |
137/354 (38.7) 217/354 (61.3) |
21/51 (41.2) 30/51 (58.8) |
NS |
| Days between symptoms onset and CCP therapy, median (IQR) | 7 (4–10) | 16 (11–29.5) | <0.001 |
| Days between symptoms onset and CCP therapy - <7 - ≥7 |
126/354 (35.6) 228/354 (64.4) |
5/51 (9.8) 46/51 (90.2) |
<0.001 |
| Days between symptoms onset and CCP therapy - <3 - ≥3 |
39/354 (11.0) 315/354 (89.0) |
0/51 (0) 51/51 (100) |
0.01 |
| CCP units transfused, mean (±SD) |
1.6 (±0.6) |
1.7 (±0.8) |
NS |
| CCP neutralizing titer, mean (±SD) |
227.2 (±184.7) |
179.6 (±170.3) |
0.04 |
| CCP neutralizing titer <160 ≥160 |
116/354 (32.8) 238/354 (67.2) |
23/51 (45.1) 28/51 (54.9) |
NS |
| CCP neutralizing titer <320 ≥320 |
239/354 (67.5) 115/354 (32.5) |
42/51 (82.3) 9/51 (17.7) |
0.03 |
Abbreviations: NS, not significant; CCP, COVID-19 convalescent plasma; BMI, body mass index; SD, standard deviation. 1 Measured before convalescent plasma transfusion.